Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation Post published:February 15, 2022 Post category:Press Release
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs Post published:January 17, 2022 Post category:Press Release
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch Post published:November 3, 2021 Post category:Press Release
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer Post published:August 17, 2021 Post category:Press Release
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline Post published:August 10, 2021 Post category:Press Release
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics Post published:June 17, 2021 Post category:Press Release
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip Post published:May 17, 2021 Post category:Press Release
Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury Post published:April 27, 2021 Post category:Press Release
Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application Post published:April 22, 2021 Post category:Press Release
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application Post published:March 19, 2021 Post category:Press Release